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Abstract
 
Chromosomal translocations juxtaposing the 
 
MYC
 
 protooncogene with regulatory sequences
 
of immunoglobulin (Ig) H chain or kappa (Ig
 
k
 
) or lambda (Ig
 
l
 
) L chain genes and effecting de-
regulated expression of 
 
MYC
 
 are the hallmarks of human Burkitt lymphoma (BL). Here we re-
port that lymphomas with striking similarities to BL develop in mice bearing a mutated human
 
MYC
 
 gene controlled by a reconstructed Ig
 
l
 
 locus encompassing all the elements required for
establishment of locus control in vitro. Diffusely infiltrating lymphomas with a typical starry sky
appearance occurred in multiple founders and an established line, indicating independence
 
from positional effects. Monoclonal IgM
 
1
 
CD5
 
2
 
CD23
 
2
 
 tumors developed from an initially
polyclonal population of B cells. These results demonstrate that the phenotype of B lineage
lymphomas induced by 
 
MYC
 
 dysregulation is highly dependent on cooperativity among the
regulatory elements that govern expression of the protooncogene and provide a new system for
studying the pathogenesis of BL.
Key words: Burkitt lymphoma • locus control region • mouse lymphoma • MYC • 
translocation
 
Introduction
 
Burkitt lymphoma (BL), first described in 1958 as a disease
of African children (1), was later recognized to occur at 10-
to 30-fold lesser frequency worldwide. The African form
of the disease, termed endemic BL, is associated with EBV
in over 95% of cases, while the non-African form, termed
sporadic BL, is EBV positive in only 10–20% of cases (for
review see reference 2). Regardless of geographic origin,
BL is invariably characterized by translocations (3) that jux-
tapose the 
 
MYC
 
 gene on chromosome 8 with IgH genes
on chromosome 14 or, less often, IgL genes on chromo-
some 2 (Ig
 
k
 
) or 22 (Ig
 
l
 
) (4, 5). The chromosome 8 break-
points are highly variable, occurring within the 
 
MYC 
 
tran-
scriptional unit or up to several hundred kilobases upstream
or downstream of 
 
MYC
 
 in cases with t(8;14) translocations
and downstream of 
 
MYC 
 
in the variant t(2;8) and t(8;22)
translocations (reference 6). Indeed, the proposed World
Health Organization Classification of Hematologic Malig-
nancies indicates that the presence of one of the 
 
MYC
 
/Ig
translocations should be considered the gold standard for
diagnosis of BL (7).
Previous efforts to develop a mouse model of BL cen-
tered on generation of transgenic mice that express the
 
MYC
 
 gene under the control of IgH or IgL regulatory se-
quences (8). These constructs induced primarily precursor
B cell as well as some surface Ig (sIg)
 
1
 
 B cell lymphomas;
however, the histopathologic features of these neoplasms
were consistent with the diagnosis of lymphoblastic lym-
phoma (LL) rather than BL. Tumors with the histologic
and phenotypic features of BL have never been described
in mice.
 
We reasoned that the IgH and IgL intronic enhancer–
 
driven 
 
MYC 
 
transgenes used by others may not have in-
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duced BL because they did not fully reflect the mode of
 
MYC
 
 activation observed in the context of BL-derived
chromosomal translocations. We therefore attempted to
reconstruct BL translocation breakpoints and designed as-
says that test for BL-specific 
 
MYC
 
 activation in vitro. To
this end, we fused the 
 
MYC 
 
gene derived from a BL-
derivative chromosome to elements of the Ig
 
k
 
 or Ig
 
l
 
 loci.
For the Ig
 
l
 
 construct, we included a 12-kb genomic frag-
ment including the Ig
 
l
 
 enhancer and three additional sites
defined by DNaseI hypersensitivity (9). The reconstructed
loci were cloned onto EBV-derived episomal vectors and
stably introduced into Raji cells (9, 10) and the condition-
ally EBV-immortalized lymphoblastoid cell line ER/EB
(11). BL-specific
 
 MYC 
 
activation was defined using the
following criteria: (a) the overall level of 
 
MYC 
 
expression
relative to expression from the endogenous normal (ER/
EB cells) or the endogenous translocated allele (Raji cells);
(b) the level of 
 
MYC 
 
expression relative to copy number;
(c) promoter shift toward predominant usage of promoter
P1 rather than P2, which is preferentially used in normal
cells (10, 12); (d) absence of transcriptional elongation
block (12, 13); (e) Epstein-Barr nuclear antigen (EBNA)2-
and latent membrane protein (LMP)1-independent prolif-
eration of conditionally EBV-immortalized ER/EB cells
(11); and (f) shift in the phenotype and growth behavior of
these cells to that of BL cells (11). According to these
highly stringent criteria, we succeeded in reconstructing all
essential features of 
 
MYC
 
 activation by the Ig
 
k
 
 and Ig
 
l
 
loci in vitro. We hypothesized (9) that the elements we
defined act in concert for 
 
MYC 
 
activation in a BL-specific
fashion function as locus control regions (LCRs) (14) that
play important roles in the physiologic regulation of IgL
expression. In this paper, we addressed whether the de-
scribed Ig
 
l
 
–MYC construct is able to recapitulate features
of BL-specific 
 
MYC
 
 activation in transgenic mice.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
A translocated 
 
MYC
 
 gene from
the human BL line IARC-BL60 with mutations in the 5
 
9
 
 se-
quences associated with promoter shift from P2 to P1 (12) was
chosen for study. The gene was placed under the control of 
 
l
 
chain regulatory sequences as shown in Fig. 1 A. The plasmid in-
serts from clone BC233A (
 
l
 
-MYC) (9) were purified for inocu-
lation of C57BL/6N (B6) fertilized eggs. Founder mice were
identified by Southern blotting using a human 
 
MYC
 
 probe. One
 
l
 
-MYC–transgenic founder was crossed with normal B6 mice to
establish a line (B6–
 
l
 
-MYC) bearing the transgene. The line was
maintained by serial crosses with normal B6 mice yielding trans-
gene heterozygotes and normal mice in each litter. Transgenic
mice were bred and maintained in a conventional colony.
 
Studies of Mice.
 
At autopsy, selected tissues were fixed in for-
malin. Sections from paraffin blocks were examined for histo-
pathologic features. Other samples were frozen for preparation of
genomic DNA and Southern blot hybridization analyses of IgH
organization. Single-cell suspensions of spleen and bone marrow
(BM) were stained for FACS
 
®
 
 analyses of cell surface Ag expres-
sion using a panel of reagents useful in distinguishing subsets of
hematopoietic cells. Cells from lymphomas were also cultured to
 
develop in vitro cell lines. Established cell lines were studied for
surface Ag by FACS
 
®
 
 and for IgH organization by Southern hy-
bridization. Western analysis of MYC protein expression was
performed using a polyclonal Ab (c-Myc [A-14]-G: sc789-G;
Santa Cruz Biotechnology, Inc.).
DNA from spleen and tumor cells was examined by Southern
hybridization for the organization of IgH using a J
 
H
 
 probe, an
ecotropic murine leukemia virus envelope–specific probe, or a
human 
 
MYC
 
 exon 2 probe using standard conditions. RNA
from these samples was used to examine mouse and human 
 
MYC
 
transcripts by RT-PCR. The same 5
 
9
 
 primer was used for both
reactions: 5
 
9
 
-CTG-CTG-GTG-GTG-GGC-GGT-GTC-TC-
3
 
9
 
. The human 
 
MYC
 
-specific 3
 
9
 
 primer was 5
 
9
 
-CGA-GCG-
GGC-GGC-CGG-CTA-3
 
9
 
, and the mouse 
 
Myc
 
-specific 3
 
9
 
primer was 5
 
9
 
-TGG-ATT-TCC-TTT-GGG-CGT-TGG-3
 
9
 
.
 
Results
 
Characteristics of Transgenic Mice.
 
Among seven founder
mice carrying the 
 
l
 
-MYC transgene, six were killed when
moribund with lymphoma between 24 and 36 d of age.
One 
 
l
 
-MYC founder that lived 106 d before dying of
lymphoma was bred to B6 mice. The progeny of the cross
with B6 and members of an established B6 line died be-
tween days 38 and 216 (Fig. 1 B) with the same gross find-
ings. In contrast to mouse follicular, splenic marginal zone,
and most diffuse large cell lymphomas that seem to origi-
nate in spleen (15), these lymphomas appeared to originate
in LNs as judged by mice presenting with advanced lym-
phadenopathy but minimal splenomegaly.
To determine whether the time course for appearance of
the lymphomas was related to transgene copy number,
DNA from tail biopsies of five 
 
l
 
-MYC founder mice was
tested by Southern hybridization using a probe specific for
human 
 
MYC
 
. Intensities of hybridizing bands were com-
pared with those generated by serially diluted transgene
plasmid (data not shown). Two founders with 1 to 2 copies
died at days 33 and 106, one with 3 copies died at day 33,
and two with 5–10 copies died at days 29 and 37. Latency
for lymphoma thus did not correlate with estimated trans-
gene copy number. Because members of an established line
were available for testing in only one instance, it is possible
that copy number estimates made from tail DNA of
founder animals could be misleading because of mosaicism.
Specificity of transgene expression was evaluated by RT-
PCR using RNA from various tissues of normal transgenic
mice and a mouse with disseminated lymphoma involving
the spleen, liver, (Fig. 1 C) and thymus (data not shown)
For mice without lymphoma, substantial levels of tran-
scripts were seen in lymphoid tissues, while nonlymphoid
tissues had undetectable or very low levels, possibly reflect-
ing the presence of lymphocytes. High levels of transcripts
were seen in all involved tissues of the mouse with lym-
phoma. In addition, FACS
 
®
 
-purified splenic T cells were
negative and sorted B cells strongly positive for 
 
MYC
 
 ex-
pression (data not shown). This indicated that the transgene
was expressed in a cell type–specific manner.
Expression of nuclear MYC protein in spleens of non-
lymphomatous transgenic mice and their control litter- 
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mates, a primary transgenic lymphoma, and two cell lines
established from lymphomas was compared in Western
blots with expression in a Burkitt cell line (Fig. 1 D). Con-
sistently low levels of protein were found only in spleens of
transgenic mice, with about fivefold higher levels seen in
the primary lymphoma and cultured cell lines. The marked
differences in expression between the primary lymphoma
and cell lines (essentially 100% B cells) and the spleen cells
of young transgenic mice (
 
z
 
40% B cells) suggest there was
significant upregulation of MYC expression as part of the
transformation process.
 
Histopathology and FACS
 
®
 
 Analyses of Transgenic Mice.
 
The histologic characteristics of lymphoid tissues from 
 
l
 
-MYC
transgene–positive mice (Fig. 2 A) and littermate controls
(Fig. 2 B) were indistinguishable through 2–3 mo of age.
FACS
 
®
 
 analyses showed that the frequencies of B cells in
transgenic spleens were 
 
z
 
70% that of control littermates
but that the B cells from mice of both genotypes expressed
comparable levels of IgM, IgD, MHC class II, CD23,
CD19, and CD45R(B220) (data not shown). T cells were
increased in frequency in transgenic spleens but exhibited
normal subset distributions and expression of cell surface
Ag (data not shown). FACS
 
®
 
 analyses of BM cells from
young transgenic and control mice (Fig. 3) showed that the
compositions of B cell differentiation stages A to F accord-
ing to the Hardy classification (16) were generally compa-
rable. The reduced frequencies of IgM
 
1
 
IgD
 
2
 
 (fraction F)
cells in transgenic BM suggests that the balance of processes
mediating positive and negative selection of immature/
transitional cells (17, 18) may be affected by enhanced ex-
pression of MYC.
In older mice presenting with lymphadenopathy, how-
ever, the spleen and LNs were diffusely infiltrated with a
highly aggressive lymphoma. Mitotic figures were numer-
ous, and large numbers of metallophilic macrophages con-
taining apoptotic bodies yielded a striking starry sky ap-
pearance (Fig. 2 C). The tissues were populated with a
monomorphic population of round cells with moderately
abundant, deeply blue cytoplasm. Nuclei were round with
moderately clumped chromatin, contained one to five large
argentophilic nucleoli, and were surrounded by a thick nu-
clear membrane without convolutions (Fig. 2 D). Infiltra-
Figure 1. Characteristics of MYC-transgenic mice. (A) Construct used for the generation of l-MYC–transgenic mice. Horizontal arrows indicate the
two MYC promoters, P1 and P2, located in the first noncoding exon (open rectangle), with the two coding exons shown by filled rectangles. Vertical ar-
rows indicate the locations of the four previously defined (9) DNaseI-hypersensitive sites (HSS) in the Igl LCR. The methods used in generating the
construct have been described elsewhere (9). (B) Mortality curve for 20 l-MYC–transgenic mice of the established strain. (C) RT-PCR analyses of
mouse and human MYC and mouse GAPDH expression in tissues of l-MYC–transgenic (TG1) and transgene-negative (TG2) littermates. BL, mouse
Burkitt lymphoma; NL, normal; Hu 4937, human breast cancer cell line; ARS6 PCT, mouse PCT cell line; K, kidney; L, liver; S, spleen; B, brain; CL,
cell line. (D) Western blot analyses of MYC expression. Nuclear proteins from the RJA BL cell line, spleens of six littermates segregating for the l-MYC
transgene (three negative and three positive), the M1 and C1 cell lines, and a primary splenic l-MYC lymphoma, 36330, were blotted with polyclonal
anti–human MYC Ab. The sizes of protein markers are indicated on the left. 
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tion of nonlymphoid tissues including liver, kidneys, lungs
and, less often, thymi was often severe.
Other lymphomas that can present with lymphadenopa-
thy in excess of splenomegaly and may exhibit a starry sky
appearance have been termed lymphoblastic lymphomas
(LLs) (15). LLs are known to be heterogeneous in lineage
(T cell versus B cell) and stage of differentiation (precursor
B cell versus sIg1 B cell) but indistinguishable by morpho-
logic and cytologic criteria. Comparisons of T cell LLs and
B cell LLs with the lymphomas of l-MYC mice showed
the LLs to comprise smaller cells with a lower mitotic in-
dex and fewer macrophages containing apoptotic bodies
(data not shown).
Studies of lymphomas from the transgenic mice showed
that they were positive for IgM, Igk (not shown),
CD45R(B220), CD19, and CD16/CD32 (Fig. 4) but were
negative for CD5 (Fig. 4) and T cell markers CD90, CD4,
and CD8 (data not shown). IgD was expressed at very low
levels or not at all. Cell lines established in culture from tis-
sues of a founder mouse (line C1) and nine backcross mice,
including line M1, were typed more extensively. The
lines expressed IgM, Igk, CD19, CD24, CD43, and
CD45R(B220) but were negative for CD5, CD23, CD30,
CD38, CD80, CD86, and CD95 (data not shown). These
phenotypes correspond closely to those characteristic of
human BL.
Characteristics of Ig Loci. To evaluate clonality, DNA
prepared from spleen cells of young l-MYC–transgenic
mice without tumors and tumors from several founder
mice, and the two cell lines cultured from primary lym-
phomas were examined for organization of IgH by South-
ern hybridization (Fig. 5). The pattern for DNA from
spleens of young mice was polyclonal, while DNA from
founders exhibited one to three distinct nongermline bands
that hybridized with a JH probe, often in association with
reduced intensity of the germline band. DNA from cell
lines exhibited complete loss of 6.6-kb germline sequences
and the presence of prominent nongermline bands (Fig. 5).
Human BL cells are almost universally sIg1, and the Ig
variable region sequences of expressed genes are mutated,
consistent with the suggestion that the transformed cells
have passed through germinal centers (19). To determine
whether the Ig genes of mouse BL were mutated, we de-
termined the expressed IgH and Igk variable sequences of
the M1 and C1 cell lines. The IgH V sequences of both
lines had single base mutations resulting in amino acid sub-
Figure 2. Histologic studies of l-MYC–transgenic mice. Sections are from spleens of (A) a transgenic mouse, (B) a normal littermate control 7 wk of
age, and (C and D) a primary lymphoma from a mouse 70 d of age. Hematoxylin and eosin 340 (A–C) or 3100 (D).1187 Kovalchuk et al. Brief Definitive Report
stitutions outside the CDRs. The third CDR of the M1
Igk gene had a single silent change in CDR3, whereas the
C1 sequences were germline (data not shown).
Discussion
The results of this study demonstrate that mice trans-
genic for a mutated human MYC protooncogene driven by
regulatory elements of the Igl locus develop lymphomas
with striking similarities to human BL. Monoclonal tumors
with the characteristic starry sky appearance of BL devel-
oped from an initially polyclonal population of B cells. LNs
and spleens of tumor-bearing mice were populated by uni-
form populations of IgM1CD191CD52CD232  cells, a
phenotype similar to that of human BL.
The histopathologic appearance of the lymphomas was
consistent for all founder mice and the progeny of the es-
tablished line, demonstrating that the phenotype cannot be
Figure 3. FACS® analyses of BM cells from (top panels) a l-MYC transgene–negative (TG2) and (bottom panels) transgene-positive (TG1) littermate.
Cells were stained with Ab to CD43, CD45R(B220), IgM, and IgD. Right panels represent examinations of cells in the D, E, F box in the correspond-
ing panel on the left. The frequencies of cells in the boxed areas as a total of all BM cells is indicated on the left panels. The proportions of the total cells
in D, E, F present in each individual fraction is given in the right panels.
Figure 4. FACS® analyses of
spleen cells from a primary lym-
phoma of a 75-d-old l-MYC–
transgenic mouse. Cells were
stained with the indicated Ab,
and the profiles were compared
with those of unstained cells.1188 Burkitt Lymphoma in the Mouse
ascribed to specific insertional mutations by the transgenes.
The time course of lymphoma development in most
founder mice was remarkably homogenous, suggesting that
position effects due to random integration of the transgene
played a minor if any role in our experiments. Other stud-
ies showed that position effects due to random integration
of transgenes may give rise to transgene silencing, compli-
cating interpretation of these experiments (14). Position-
independent expression of a transgene is recognized as one
of the hallmarks of locus control.
Copy number–dependent expression of linked trans-
genes, established in studies of b globin genes regulated by
the homologous LCR, is felt to be a second characteristic
of LCR regulation (14). Some studies, however, suggest
that inclusion of this standard as an absolute requirement
for demonstration of locus control may be unrealistically
stringent, particularly if the reporters are genes not nor-
mally controlled by the LCR. For example, the b globlin
LCR confers neither position-independent nor copy
number–dependent expression on a lacZ transgene, even
though both features hold if the same LCR is used to reg-
ulate a linked b globin gene (20). Parallel studies of the
IgH 39 LCR showed that a linked b globin gene is ex-
pressed in a position- but not copy number–independent
manner (21). Our studies of MYC regulation by the puta-
tive Igl LCR also indicated a lack of copy number–depen-
dent expression through the indirect readout of latency for
lymphoma appearance. This “reporter phenotype” is
much less direct than determining b galactosidase activity
or b globin levels, because deregulated expression of MYC
is not sufficient to induce transformation (8). We therefore
tentatively conclude that establishment of locus control
suggested by in vitro studies using the l-MYC construct
also occurs in vivo.
Our results differ from those described for mice bearing a
series of different MYC transgenes controlled by the in-
tronic IgH and Igk enhancers (8). Mice with Em-Myc
transgenes developed lymphomas with near 100% inci-
dence. All tumors had lymphoblastic morphology, and
most were sIg2 with IgL in germline configuration, fea-
tures consistent with the diagnosis of precursor B cell LL;
however, some tumors were noted to be sIg1. The propor-
tions of pre-B to B cell phenotypes induced by the MYC
gene linked to an enhancer on a minigene construct may
be affected by transgene copy number, with high numbers
of tandem copies and high-level MYC expression favoring
immature tumors. This view is supported by the observa-
tion that mice carrying single-copy human IgH/c-MYC
YAC transgenes developed only IgM1 lymphomas (22);
histologic studies of these tumors were not reported.
Features of the latent period for lymphoma development
differ markedly for the Em-Myc and l-MYC–transgenic
mice. The BM of Em-Myc mice 4–7 wk of age is domi-
nated by large pre-B cells, and enlarged spleens were strik-
ingly abnormal in containing z25% pre-B cells (23). In
contrast, the BMs of l-MYC–transgenic mice of compara-
ble age were barely distinguishable from those of littermate
controls. The slight reductions in the frequency of trans-
genic BM B cells were reflected in slightly reduced B cell
numbers in otherwise normal spleens.
The previously developed Myc transgenics and our new
strain also have some features in common. Development of
monoclonal disease from a polyclonal background of cells
uniformly expressing MYC is characteristic of both Em-
Myc– and l-MYC–transgenic mice and is consistent with
the concept of a multistep process leading to the malignant
transformation of normal cells. It is also in keeping with
previous studies demonstrating that Myc translocations oc-
cur in preneoplastic B cells in nontransgenic mice prone to
plasmacytoma (PCT) development after inoculation of
pristane (24).
Development of pre-B cell lymphomas in Em-Myc–
transgenic mice and mature B cell lymphomas in l-MYC
mice might be related to the fact that the Em enhancer is
active already in the pre-B cell stage, whereas the L chain
enhancers used in the current studies become operative
several days later in B cell differentiation. This seems un-
likely, because human BL cases with IgH-related t(8;14)
translocations are histologically and phenotypically indistin-
guishable from cases with variant IgL translocations, indi-
cating that the overall activity imposed by the different Ig
loci on the translocated MYC gene is very similar if not
identical.
One possible explanation for this seeming paradox is that
the 39 Ig enhancers play a decisive role in the development
of BL. This concept centers on the fact that the MYC gene
is invariably located upstream from the 39 enhancers of
the Ig loci involved in the translocation. For the IgL loci, the
activity of single Ig enhancers is weak in comparison to the
combination of enhancers that drive Ig expression under
Figure 5. Southern blot analyses
of H chain organization in l-MYC–
transgenic mice. DNA from spleen
cells of a 6-wk-old transgenic mouse
without a lymphoma (lane 1), two
founder mice with primary lympho-
mas (lanes 2 and 3), and the M1
(lane 4) and C1 (lane 5) cell lines
generated from a founder mouse and
a mouse from the established trans-
genic line, respectively, was digested
with EcoRI separated and hybrid-
ized with the J11 JH probe. Size
markers are indicated on the left.1189 Kovalchuk et al. Brief Definitive Report
physiologic conditions (9, 10). While 39 enhancers function
constitutively to interact with 59 enhancers, they are also
responsive to physiologic stimuli, including cross-linking of
the BCR (25) or ligation of CD40 (26) as well as activation
by LPS plus CD40 (27). We therefore propose that B cell
stimulation leading to activation of Ig 39 enhancers results
in enforced high-level MYC expression as a critical deter-
minant of BL pathogenesis. A requirement for an intact
BCR in this signaling matrix could explain why only ma-
ture lymphomas with functional Ig receptors are induced.
Expression of a functional BCR as an invariant feature of
BL suggests antigenic stimulation as a possible component
of pathogenesis. This concept is supported by findings that
almost all IgH V region sequences from endemic, sporadic,
and AIDS-associated BL cases were mutated to varying ex-
tents, ranging from a single point mutation up to 15% of
IgH V and J region sequences (19). These data indicate
that, for most cases, the cells of origin were Ag-experi-
enced and had passed through germinal centers. The cell
lines established from the transgenic mice had single base
changes in the productive H chain and L chain alleles, none
affecting structure of the CDRs.
Ig hypermutation after antigenic stimulation may be a
consistent feature of human BL because it provides the
means of accumulating mutations in the coding region of
the translocated MYC gene, rendering the MYC protein
less regulatable and more oncogenic (28). If so, we would
predict that a wild-type MYC gene substituted for the mu-
tant allele in our constructs would be less oncogenic. A sec-
ond prediction from this model is that lymphomas would
develop with longer latency in mice raised under specific
pathogen-free conditions. Both of these issues are now be-
ing investigated.
Our finding that a reconstructed BL chromosomal
breakpoint can recapitulate essential features of the disease
in mice strongly supports the notion that there is a link be-
tween cytogenetic aberrations and the histopathologic and
immunophenotypic presentation of a given tumor and that
this link is conserved between mice and humans. Nonethe-
less, it is noteworthy that the same type of chromosomal
translocations observed in human BL are hallmarks of PCT
in mice (29). In PCT, the Myc/IgH breakpoints are usually
located in the Iga switch region, whereas in human BL,
they occur most frequently in the Igm joining or switch re-
gion; however, BL cases with breakpoints in Iga have been
reported, as have PCT mice with breakpoints in the Igm
gene. Furthermore, there is no apparent difference in the
molecular architecture of variant IgL translocations in BL
versus PCT that might explain the different histopathologic
presentations of these lymphomas.
The reason that apparently identical chromosomal trans-
locations are associated with different hematologic malig-
nancies such as BL and PCT is not understood. PCT de-
velops in peritoneal granulomas induced by mineral oil and
can be prevented by treatment with the antiinflammatory
drug indomethacin (30). This suggests that the microenvi-
ronment in which a tumor arises impacts on the stage to
which the malignant cell will differentiate. According to
this model, pristane treatment of our transgenic mice
should give rise to PCT, presumably before the onset of
BL. Attempts to address this question directly are in
progress.
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